2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
09:30 a.m. - 11:00 a.m.
MCCNO - R02-R05
Treatment Considerations, Combination Therapy, Drug Development, Diseases, Myeloid Malignancies, Chronic Myeloid Malignancies, Research, MPN, Clinical Research, Clinical Trials, Study Population, Human, Adult
PAPER

525 Long-term outcomes of pelabresib (PELA) plus ruxolitinib (RUX) in Janus kinase inhibitor (JAKi)-naive myelofibrosis (MF): Week 144 results from the Phase 3 MANIFEST-2 study

Andrew T Kuykendall, MD, Sebastian Grosicki, MD PhD2, Raajit K. Rampal, MD, PhD3, Alessandro Vannucchi, MD4, John O. Mascarenhas, MD5, Moshe Talpaz, MD6, Claire Harrison, DM7, Jean-Jacques Kiladjian8, Ruben Mesa, MD9, Dominik Chraniuk, MD10, Elisabetta Abruzzese, MD, PhD11, Prithviraj Bose, MD12, Aaron T. Gerds, MD, MS13, Francesca Palandri, MD, PhD14, Sung-Eun Lee, MD, PhD15, Alessandro Lucchesi, MD, PhD16, Stephen Oh, MD, PhD17, Andrea Patriarca, MD, PhD18, Alberto Alvarez-Larran, MD19, David Lavie, MD20, Monika Wroclawska, MD, MBA21, Rajendra Jinwal, MD22, Zhiyu Sui23, Vikas Gupta, MD FRCP, FRCPath24
1 Moffitt Cancer Center, Tampa, Florida, United States
2 Medical University of Silesia, Katowice, Poland
3 Memorial Sloan Kettering Cancer Center, New York, New York, United States
4 AOU Careggi, Florence, Italy
5 Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, United States
6 University of Michigan, Ann Arbor, Michigan, United States
7 Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom
8 Clinical Investigation Center, Hôpital Saint-Louis, Université Paris Cité, Inserm, Paris, France
9 Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States
10 Wojewódzki Szpital Zespolony im. L. Rydygiera Stacja Ratownictwa Medycznego, Torun, Poland
11 S. Eugenio Hospital, Tor Vergata University, ASL Roma 2, Rome, Italy
12 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
13 Cleveland Clinic and Case Comprehensive Cancer Center, Cleveland, Ohio, United States
14 IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Bologna, Italy
15 Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Rep. of South
16 IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy
17 Washington University School of Medicine in St. Louis, Saint Louis, Missouri, United States
18 AOU Maggiore della Carità and University of Eastern Piedmont, Novara, Italy
19 Hospital Clínic de Barcelona (IDIBAPS), Barcelona, Spain
20 Hadassah-Hebrew University Medical Center, Jerusalem, Israel
21 Novartis Pharma AG, Basel, Switzerland
22 Novartis Pharma AG, Basel, Switzerland
23 Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States
24 Princess Margaret Cancer Centre, Toronto, Ontario, Canada

Background

Janus kinase inhibitor (JAKi) monotherapy, the myelofibrosis (MF) standard of care, improves splenomegaly and symptom burden but has inadequate durability of treatment (tx) response in some patients (pts). There is an unmet need for therapeutic approaches that provide durable responses, address the underlying MF disease biology, and improve survival. Surrogate endpoints for overall survival (OS) are also needed, with spleen response a promising candidate requiring further validation. Pelabresib (PELA), an oral, investigational bromodomain and extra-terminal domain (BET) inhibitor in development for MF, regulates transcriptional pathways driving MF pathogenesis and acts synergistically with ruxolitinib (RUX) to improve the underlying MF pathobiology. The Phase 3 MANIFEST-2 study (NCT04603495) investigating PELA+RUX in pts with JAKi-naive MF met its primary endpoint of ≥35% reduction in spleen volume from baseline (SVR35) at Week (W) 24. We report long-term W144 results.

Methods

MANIFEST-2 is a double-blind, randomized study in pts with JAKi-naive MF. Pts were randomized 1:1 to receive PELA or placebo (PBO) once daily with RUX twice daily. In the current analysis, efficacy and safety endpoints were assessed, including SVR35, total symptom score (TSS), hemoglobin (Hb) response, and survival outcomes. A post-hoc analysis assessed the association between SVR35 at W24 and OS at W144.

Results

A total of 430 pts were randomized to PELA+RUX (n=214) and PBO+RUX (n=216). Median study duration was 153 W (interquartile range, 92-176). At W144 data cutoff (December 12, 2025), 39.3% of pts remained on study tx. Overall, 59.8% of pts discontinued tx: 59.3% with PELA+RUX vs 60.2% with PBO+RUX, with the most common reason for tx discontinuation being adverse events (AEs) in 25.7% vs 18.5% of pts, respectively.

At W144, SVR35 was achieved by 36.9% with PELA+RUX vs 24.1% with PBO+RUX in the intent-to-treat population (pts lost to follow-up were counted as non-responders). Median duration of splenic response has not been reached with PELA+RUX and was 142.4 W with PBO+RUX (HR, 0.64; 95% CI 0.44-0.94). Change in absolute TSS from baseline was -15.34 with PELA+RUX vs -13.14 with PBO+RUX (mean difference 2.2) based on the 7 Myelofibrosis Symptom Assessment Form (MFSAF) symptom scores. A ≥50% reduction in TSS from baseline (TSS50) was achieved by 28.5% with PELA+RUX vs 23.6% with PBO+RUX. Dual SVR35/TSS50 response was seen in 22.9% with PELA+RUX vs 14.4% with PBO+RUX. Hb response (defined as ≥1.5 g/dL increase in Hb from baseline) was achieved in 21.5% with PELA+RUX vs 12.5% with PBO+RUX.

In an SVR35 and OS correlation analysis (irrespective of tx), pts achieving SVR35 at W24 had a 55% lower risk of death vs non-responders (HR, 0.45; 95% CI 0.25-0.81; P=.0092). When SVR is considered as a continuous endpoint, each additional 1% spleen volume reduction was associated with a ~2.2% lower risk of death. Progression-free survival events occurred in 14.0% with PELA+RUX vs 19.0% with PBO+RUX (HR, 0.83; 95% CI 0.51-1.35). Deaths were reported in 17.3% with PELA+RUX vs 20.4% with PBO+RUX (HR, 0.98; 95% CI 0.63-1.53). Leukemic transformations were reported in 5.6% of pts with PELA+RUX vs 4.2% with PBO+RUX.

In total, 212 and 214 pts in the PELA+RUX and PBO+RUX arms received tx and were included in the safety analyses; two pts in each arm were randomized but not dosed. Tx-emergent AEs were similar to those reported previously; differences (>10% of pts) between PELA+RUX vs PBO+RUX included anemia (all grade: 55.2% vs 59.8%; grade ≥3: 29.2% vs 43.9%), thrombocytopenia (60.4% vs 48.6%; 20.8% vs 9.8%), and dysgeusia (19.8% vs 3.7%; 0.5% vs 0%).

Conclusions

The findings represent the longest follow-up to date of a randomized combination study in JAKi-naive MF. Over nearly 3 years of follow-up, PELA+RUX continued to demonstrate deep and durable splenic responses and improvements in symptoms (across all 7 MFSAF scores) and Hb response, with a well-tolerated safety profile. The consistency of the findings across timepoints underscores the durability of clinical benefit and the favorable benefit–risk profile of PELA+RUX. A post-hoc correlation analysis demonstrated a strong association between achieving SVR and improved OS, suggesting SVR35 may be a good prognostic factor for OS. Overall, the W144 findings support the combination of PELA+RUX as a well-tolerated therapy with durable clinical benefits and potential for disease modification in MF.
Andrew T Kuykendall, MD: Novartis - Honoraria; Incyte - Honoraria; Karyopharm - Honoraria; Disc Medicine - Honoraria; GlaxoSmithKline - Honoraria; Geron - Honoraria; Cogent - Honoraria; Bristol Myers Squibb - Honoraria; Blueprint - Honoraria; PharmaEssentia - Honoraria; Sobi - Honoraria; Kartos/Ipsen - Research Funding; Geron - Research Funding; Incyte - Research Funding; Blueprint - Research Funding; Protagonist - Research Funding; Novartis - Research Funding; AJAX/Eli Lilly - Research Funding; GlaxoSmithKline - Research Funding; Prelude - Research Funding; Bristol Myers Squibb - Research Funding; Takeda - Research Funding; Dompei - Research Funding; Janssen - Research Funding; Disc Medicine - Research Funding; AbbVie - Consultancy (Includes expert testimony); Karyopharm - Consultancy (Includes expert testimony); Agios - Consultancy (Includes expert testimony); Merck - Consultancy (Includes expert testimony); Janssen - Consultancy (Includes expert testimony); Disc Medicine - Consultancy (Includes expert testimony); Protagonist - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); Calytrix - Consultancy (Includes expert testimony); Damora - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); Silence Therapeutics - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony); PharmaEssentia - Consultancy (Includes expert testimony)